R&D News | pharmaphorum

News

Map showing the East West Rail route that lies at the heart of the Oxford-Cambridge supercluster plan

AZ joins call for new UK PM to back Oxford-Cambridge hub

In a letter to the new UK Prime Minister Keir Starmer, leading figures in industry and academia have called for a plan to turn the Oxford-Cambridge region into the 'crown jewel' of the nati

News

Shingles shot could be a simple way to delay dementia

Vaccination with GSK's recombinant shingles vaccine, Shingrix, could delay the onset of dementia, according to researchers in the UK.

News

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC

FDA reviewers were so frustrated by AstraZeneca's application for Imfinzi as a treatment before and after surgery for resectable non-small cell lung cancer (NSCLC) that they voted for a ret

News

Ipsen builds again, licensing Day One glioma drug

Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceutical

News

Can Pfizer, Sangamo energise haemophilia A gene therapy?

There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow.

News

Biogen, Sage drug for essential tremor flunks mid-stage test

Biogen's $3 billion alliance with Sage Therapeutics has suffered another setback after their drug for essential tremor failed to move the needle in a phase 2 study.

AZ joins call for new UK PM to back Oxford-Cambridge hub

Shingles shot could be a simple way to delay dementia

ODAC unpicks AZ's Imfinzi trial in perioperative NSCLC

Ipsen builds again, licensing Day One glioma drug

Can Pfizer, Sangamo energise haemophilia A gene therapy?

Biogen, Sage drug for essential tremor flunks mid-stage test

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks